| SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. | sarcoma, |
| Induction of p21(WAF1/CIP1) by human synovial sarcoma-associated chimeric oncoprotein SYT-SSX1. | sarcoma, |
| [Molecule binds to SYt-SSX1 chimeric oncogene products of synovial sarcoma]. | sarcoma, |
| The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. | sarcoma, |
| Human synovial sarcoma proto-oncogene Syt is essential for early embryonic development through the regulation of cell migration. | sarcoma, |
| The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. | sarcoma, |
| Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. | sarcoma, |
| Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. | sarcoma, |
| Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. | sarcoma, |
| SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier. | sarcoma, |
| Synovial sarcoma (SS) is considered as high-grade tumors with a poor prognosis. Novel therapies targeted at fusion oncogene, SS18-SSX-derived peptide vaccine, epidermal growth factor receptor, and vascular endothelial growth factor are the future hope in SS. | sarcoma, |
| p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion. | None |
| Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. | None |
| The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. | None |
| The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. | None |
| The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells. | None |
| provides evidence that, in the appropriate context, expression of the SYT-SSX2 oncogene leads to loss of polycomb function | None |
| Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. | None |
| Data indicate that the oncogene SS18-SSX1 promotes tumorigenesis by increasing the expression of SHC SH2-domain binding protein 1 (SHCBP1), which normally acts as a tumor promoting factor. | None |